周二盘中，再生元制药公司（Regeneron Pharmaceuticals）股价大涨6.61%，引发投资者广泛关注。这一显著涨幅主要源于公司发布的第三季度财报远超市场预期。
根据最新公布的财务报告，再生元制药第三季度调整后每股收益达到11.83美元，远超分析师预期的9.59美元。公司第三季度总营收为37.5亿美元，同比增长1%，高于市场预期的35.9亿美元。这一亮眼业绩主要得益于其主打产品的强劲需求，尤其是与赛诺菲合作开发的湿疹治疗药物Dupixent和皮肤癌治疗药物Libtayo的表现突出。
具体来看，Libtayo的销售额达到3.65亿美元，超出预期的3.4375亿美元。与拜耳公司联合开发的8毫克大剂量版Eylea在美国的销售额同比增长10%，达到4.31亿美元。分析师指出，尽管Eylea面临来自仿制药和竞争对手产品的压力，但其特许经营权仍然稳定。再生元制药正努力将客户转向新配方的Eylea HD，以延长患者的注射间隔时间，从而巩固市场地位。这些积极因素共同推动了投资者信心，促使股价大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.